SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced an upcoming presentation entitled “Phosphatidylserine suppresses T cells through GPR174, and co-inhibition of adenosine receptors and GPR174 synergistically enhances T-cell responses” at the American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy, which is being held November 17 - 20, 2019 in Boston, Massachusetts.
Marc Gavin, Ph.D., Omeros’ Director of Immunology, will present the company’s new findings that phosphatidylserine, a product of cell stress and death that is abundant in the tumor microenvironment (TME), directly stimulates GPR174 and attenuates T-cell responses.
Adenosine, another product of the TME, is well known to stimulate the same suppressive pathways through different GPCRs, and inhibition of both pathways—with adenosine receptor antagonists and with Omeros’ novel GPR174 inhibitors—results in maximal enhancement of T-cell function, which should translate to effective resistance to the immunosuppressive nature of the TME.
The data will also feature new findings from animal tumor models, which validate GPR174 inhibition for cancer immunotherapy.
Designated B45, the poster will be presented in Poster Session B on Tuesday, November 19, 4:30 p.m. to 7:00 p.m.
About Omeros Corporation
Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. In addition to its commercial product OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3%, Omeros has multiple Phase 3 and Phase 2 clinical-stage development programs focused on complement-mediated disorders and substance abuse, as well as a diverse group of preclinical programs including GPR174, a novel target in immuno-oncology that modulates a new cancer immunity axis recently discovered by Omeros. Small-molecule inhibitors of GPR174 are part of Omeros’ proprietary G protein-coupled receptor (GPCR) platform through which it controls 54 new GPCR drug targets and their corresponding compounds. The company also exclusively possesses a novel antibody-generating platform.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the “safe harbor” created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “likely”, “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “prospects,” “should,” “slated,” “targeting,” “will,” “would” and similar expressions and variations thereof. Forward-looking statements, including statements regarding Omeros’ research and development programs and the therapeutic application of Omeros’ research findings, are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. Omeros’ actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, unproven preclinical and clinical development activities, availability and timing of data from preclinical or clinical studies and the results of such studies, risks associated with product commercialization and commercial operations, regulatory actions and oversight, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors described under the heading “Risk Factors” in the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2019. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.
Source: Omeros Corporation